Iterion Therapeutics Announces Promising Phase 1b Data for Tegavivint in Combination with Osimertinib in First-Line EGFR-Mutated Non-Small Cell Lung Cancer
Why now
Thesis: Early Phase 1b efficacy data can move biotech sponsor shares
Catalyst to watch: Maturation of Phase 1b data or next trial stage
Main risk: Phase 1b data and sponsor outside allowed ticker set
Why it matters
Early-stage biotech efficacy data can move the sponsor's shares, but the company is not in the allowed ticker set and data are Phase 1b.
Details
Combination demonstrating 79% objective response rate (ORR), including complete responses (CRs) in 16% of patients (compared to 1% historically for osimertinib alone) Median progression-free survival (mPFS) of 19.9 months and median overall survival (mOS) of 48.8 months observed in the...
Related assets & topics
HealthcareSources
- prnewswire · 2026-09-22 12:09 UTC